BEVERLY, Mass., August 28, 2023--(BUSINESS WIRE)--Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, announced today that President & CEO Todd Zion, Ph.D., will present at the 2023 Animal Health Summit in Kansas City, MO on August 28, 2023.
In his presentation, part of the Emerging Companies session, Dr. Zion will highlight Akston’s corporate history, the market opportunities the company is pursuing, and how it uses its Ambifect™ Fc-fusion platform to invent novel, high-value, therapies. He will also discuss Akston’s integrated capabilities, from invention to development and commercial production, and why this can be the key to bringing new products to market faster and at lower cost.
Akston’s most advanced candidates are AKS-321d and AKS-425c, groundbreaking once-a-week insulins to treat canine and feline diabetes. Both are licensed to and are being developed in partnership with Dechra Pharmaceuticals, Plc, a global veterinary pharmaceuticals company. These can provide a significant leap forward in the standard of care to improve the quality of life for pets and their owners by replacing the current twice daily insulin injection regimen. Other candidates in Akston’s development pipeline include AKS-544d, which targets chronic pain in canines, and AKS-197d, an insulin receptor down-regulator for treating canine cancers.
"We believe that protein therapeutics are poised to revolutionize Companion Animal Health, just as they did for human health 20 years ago," said Dr. Zion. "The positive feedback from owners of animals treated so far with AKS-321d and AKS-425c underscores our belief that, upon securing regulatory approval, both products can achieve rapid market adoption and could attain blockbuster status for Animal Health therapeutics."
About Akston Biosciences
Akston Biosciences Corporation invents, develops, and manufactures breakthrough protein therapeutics for Companion Animal Health. It was founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co.). Akston uses its Ambifect™ Fc-fusion platform to design its own novel candidates and operates a multi-kilogram-scale cGMP biologics clean-room factory dedicated to Animal Health therapeutic production. The company also provides Contract Development and Manufacturing Organization (CDMO) services for other Animal Health companies. Additional information is available at www.akstonbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828431008/en/
Birnbach Communications for Akston Biosciences
1-508-224-7905 | email@example.com